| Item Type | Name |
|
Concept
|
Angiotensin II
|
|
Concept
|
Angiotensin-Converting Enzyme Inhibitors
|
|
Concept
|
Receptors, Angiotensin
|
|
Concept
|
Receptor, Angiotensin, Type 1
|
|
Concept
|
Angiotensin II Type 1 Receptor Blockers
|
|
Concept
|
Renin-Angiotensin System
|
|
Concept
|
Angiotensin Receptor Antagonists
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy.
|
|
Academic Article
|
Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria.
|
|
Academic Article
|
Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy.
|
|
Academic Article
|
Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ?
|
|
Academic Article
|
Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy.
|
|
Academic Article
|
Socioeconomic impact of diabetic nephropathy: can we improve the outcome?
|
|
Academic Article
|
Renal mortality associated with non-insulin-dependent diabetes mellitus.
|
|
Academic Article
|
Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients.
|
|
Academic Article
|
The renin-angiotensin system in diabetic nephropathy: the endothelial connection.
|
|
Academic Article
|
Angiotensin II receptor blockers in hypertension and renal disease.
|
|
Academic Article
|
The use of antisense oligonucleotides to establish autocrine angiotensin growth effects in human neuroblastoma and mesangial cells.
|
|
Academic Article
|
Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease.
|
|
Academic Article
|
Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation.
|
|
Academic Article
|
Antihypertensive therapy and the risk of type 2 diabetes mellitus.
|
|
Academic Article
|
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
|
|
Academic Article
|
Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury.
|
|
Academic Article
|
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
|
|
Academic Article
|
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
|
|
Academic Article
|
When to discontinue ACE inhibitors for nephropathy.
|
|
Academic Article
|
Diabetic hypertensive patients: improving their prognosis.
|
|
Academic Article
|
A practical approach to achieving recommended blood pressure goals in diabetic patients.
|
|
Academic Article
|
Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.
|
|
Academic Article
|
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
|
|
Academic Article
|
A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease.
|
|
Academic Article
|
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models.
|
|
Academic Article
|
Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals.
|
|
Academic Article
|
Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study.
|
|
Academic Article
|
The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
|
|
Academic Article
|
Heart failure as a cause for hospitalization in chronic dialysis patients.
|
|
Academic Article
|
Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial.
|
|
Academic Article
|
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).
|
|
Academic Article
|
Evaluation and treatment of patients with systemic hypertension.
|
|
Academic Article
|
Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring.
|
|
Academic Article
|
Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker.
|
|
Academic Article
|
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
|
|
Academic Article
|
Diabetes and chronic kidney disease: tragedy and challenge.
|
|
Academic Article
|
How to adjust ACE inhibitors and ARBs in diabetes?
|
|
Academic Article
|
Clinical implications of blockade of the renin-angiotensin system in management of hypertension.
|
|
Academic Article
|
Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction.
|
|
Academic Article
|
The role of calcium antagonists in chronic kidney disease.
|
|
Academic Article
|
Blood pressure control and nephroprotection in diabetes.
|
|
Academic Article
|
Protecting renal function in the hypertensive patient: clinical guidelines.
|
|
Academic Article
|
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
|
|
Academic Article
|
Implications of albuminuria on kidney disease progression.
|
|
Academic Article
|
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
|
|
Academic Article
|
ACE inhibitor for a diabetic patient with normal blood pressure?
|
|
Academic Article
|
Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
|
|
Academic Article
|
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
|
|
Academic Article
|
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes.
|
|
Academic Article
|
Is ethnicity a factor in choice of antihypertensive drug?
|
|
Academic Article
|
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
|
|
Academic Article
|
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial.
|
|
Academic Article
|
The cardiometabolic syndrome and calcium channel blocker combination drugs.
|
|
Academic Article
|
Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
|
|
Academic Article
|
Clinical importance of microalbuminuria in diabetes and hypertension.
|
|
Academic Article
|
Antihypertensive therapy in the presence of proteinuria.
|
|
Academic Article
|
Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker.
|
|
Academic Article
|
Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient?
|
|
Academic Article
|
Slowing nephropathy progression: focus on proteinuria reduction.
|
|
Academic Article
|
Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control.
|
|
Academic Article
|
Who should be treated with combination therapy as initial treatment for hypertension?
|
|
Academic Article
|
beta-blocker use and diabetes symptom score: results from the GEMINI study.
|
|
Academic Article
|
Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus.
|
|
Academic Article
|
Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
|
|
Academic Article
|
ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?
|
|
Academic Article
|
The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states.
|
|
Academic Article
|
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
|
|
Academic Article
|
Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective.
|
|
Academic Article
|
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.
|
|
Academic Article
|
Newer combination therapies in the management of hypertension: an update.
|
|
Academic Article
|
Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
|
|
Academic Article
|
Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade.
|
|
Academic Article
|
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
|
|
Academic Article
|
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study.
|
|
Academic Article
|
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.
|
|
Academic Article
|
Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons?
|
|
Academic Article
|
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
|
|
Academic Article
|
Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?
|
|
Academic Article
|
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.
|
|
Academic Article
|
The kidney, hypertension, and remaining challenges.
|
|
Academic Article
|
Resistant hypertension: an overview of evaluation and treatment.
|
|
Academic Article
|
The current state of RAAS blockade in the treatment of hypertension and proteinuria.
|
|
Academic Article
|
Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it?
|
|
Academic Article
|
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.
|
|
Academic Article
|
Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.
|
|
Academic Article
|
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
|
|
Academic Article
|
Are there effects of renin-angiotensin system antagonists beyond blood pressure control?
|
|
Academic Article
|
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
|
|
Academic Article
|
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
|
|
Academic Article
|
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
|
|
Academic Article
|
The continuum of blood pressure risk: when is the best time to intervene?
|
|
Academic Article
|
24-hour ambulatory blood pressure in the ACCOMPLISH trial.
|
|
Academic Article
|
Cardiovascular events during differing hypertension therapies in patients with diabetes.
|
|
Academic Article
|
More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors.
|
|
Academic Article
|
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
|
|
Academic Article
|
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
|
|
Academic Article
|
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
|
|
Academic Article
|
The evolution of antihypertensive therapy: an overview of four decades of experience.
|
|
Academic Article
|
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
|
|
Academic Article
|
Influence of microalbuminuria in achieving blood pressure goals.
|
|
Academic Article
|
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.
|
|
Academic Article
|
The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
|
|
Academic Article
|
Antihypertensive therapy and progression of diabetic renal disease.
|
|
Academic Article
|
Renal effects of antihypertensive medications: an overview.
|
|
Academic Article
|
Renal adaptation to the failing heart. Understanding the cascade of responses.
|
|
Academic Article
|
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
|
|
Academic Article
|
Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers.
|
|
Academic Article
|
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
|
|
Academic Article
|
An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements.
|
|
Academic Article
|
Management of hypertension in the elderly population.
|
|
Academic Article
|
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
|
|
Academic Article
|
Telmisartan in incipient and overt diabetic renal disease.
|
|
Academic Article
|
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
|
|
Academic Article
|
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection.
|
|
Academic Article
|
Renal adaptation to the failing heart. Avoiding a 'therapeutic misadventure'.
|
|
Academic Article
|
Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells.
|
|
Academic Article
|
Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes.
|
|
Academic Article
|
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.
|
|
Academic Article
|
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
|
|
Academic Article
|
Renal hemodynamic changes in heart failure.
|
|
Academic Article
|
ASH position paper: treatment of hypertension in patients with diabetes-an update.
|
|
Academic Article
|
Effects of angiotensin II receptor blockers on diabetic nephropathy.
|
|
Academic Article
|
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.
|
|
Academic Article
|
Pediatrics: blood pressure target for renoprotection in children.
|
|
Academic Article
|
Combination therapy in hypertension.
|
|
Academic Article
|
Fixed-dose combination and chronic kidney disease progression: which is the best?
|
|
Academic Article
|
Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy.
|
|
Academic Article
|
Intensive blood-pressure control in hypertensive chronic kidney disease.
|
|
Academic Article
|
Pathogenesis and clinical physiology of hypertension.
|
|
Academic Article
|
Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?
|
|
Academic Article
|
A reappraisal of renin-angiotensin system blockade on microalbuminuria development: do they offer anything unique?
|
|
Academic Article
|
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
|
|
Academic Article
|
Treatment of renal failure and blood pressure.
|
|
Academic Article
|
ACE inhibitor-mediated attenuation of mesangial cell growth. A role for endothelin.
|
|
Academic Article
|
Evolution of drugs that preserve renal function.
|
|
Academic Article
|
Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.
|
|
Academic Article
|
ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence.
|
|
Academic Article
|
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
|
|
Academic Article
|
Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.
|
|
Academic Article
|
Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy.
|
|
Academic Article
|
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
|
|
Academic Article
|
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
|
|
Academic Article
|
Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting.
|
|
Academic Article
|
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.
|
|
Academic Article
|
Renin-angiotensin blockade and kidney disease.
|
|
Academic Article
|
The future of blood pressure control in a population with a growing girth.
|
|
Academic Article
|
Is blockade of the renin-angiotensin system appropriate for all patients with diabetes?
|
|
Academic Article
|
Dual RAAS blockade is desirable in kidney disease: con.
|
|
Academic Article
|
Hypertensive nephropathy: prevention and treatment recommendations.
|
|
Academic Article
|
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
|
|
Academic Article
|
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.
|
|
Academic Article
|
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
|
|
Academic Article
|
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.
|
|
Academic Article
|
The author replies.
|
|
Academic Article
|
The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control.
|
|
Academic Article
|
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.
|
|
Academic Article
|
The past, present and future of renin-angiotensin aldosterone system inhibition.
|
|
Academic Article
|
Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies.
|
|
Academic Article
|
Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.
|
|
Academic Article
|
Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated?
|
|
Academic Article
|
The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension.
|
|
Academic Article
|
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.
|
|
Academic Article
|
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.
|
|
Academic Article
|
Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
|
|
Academic Article
|
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.
|
|
Academic Article
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
|
Academic Article
|
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
|
|
Academic Article
|
New agents for hyperkalemia.
|
|
Academic Article
|
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
|
|
Academic Article
|
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
|
|
Academic Article
|
Advances in treatment of hyperkalemia in chronic kidney disease.
|
|
Academic Article
|
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
|
|
Academic Article
|
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension.
|
|
Academic Article
|
Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
|
|
Academic Article
|
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
|
|
Academic Article
|
Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
|
|
Academic Article
|
Renal Denervation: a Field in Flux.
|
|
Academic Article
|
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.
|
|
Academic Article
|
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
|
|
Academic Article
|
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
|
|
Academic Article
|
Mineralocorticoid antagonists in chronic kidney disease.
|
|
Academic Article
|
Relative antihypertensive and glomeruloprotective efficacies of enalapril and candesartan cilexetil in the remnant kidney model.
|
|
Academic Article
|
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension.
|
|
Academic Article
|
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
|
|
Academic Article
|
Baseline characteristics and enrichment results from the SONAR trial.
|
|
Academic Article
|
Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
|
|
Academic Article
|
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
|
|
Academic Article
|
Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
|
|
Academic Article
|
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
|
|
Academic Article
|
Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.
|
|
Academic Article
|
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
|
|
Academic Article
|
Hypertension.
|
|
Academic Article
|
Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia.
|
|
Academic Article
|
Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
|
|
Academic Article
|
Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension.
|
|
Academic Article
|
Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial.
|
|
Academic Article
|
Optimizing Blood Pressure Control Without Adding Anti-Hypertensive Medications.
|
|
Academic Article
|
Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
|
|
Academic Article
|
Novel antihypertensive agents for resistant hypertension: what does the future hold?
|
|
Grant
|
AASK Cohort Study
|
|
Academic Article
|
Slowing the Progression of Diabetic Kidney Disease.
|